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ABSTRACT
Despite increasing antimicrobial resistance and multiple drug resistance in clinical isolates of both
Gram-positive and Gram-negative bacteria, there are few novel antimicrobial agents in development.
The few new agents that have been recently licensed have tended to have narrow spectra of activity,
focused on Gram-positive pathogens, especially methicillin-resistant Staphylococcus aureus (MRSA). This
situation is rightly causing concern among clinicians and public health authorities worldwide. This
article reviews available data on three new antibacterials currently in development. The cephalosporin
ceftobiprole is active against MRSA, Enterococcus faecalis and penicillin-resistant Streptococcus pneumo-
niae, but otherwise has a spectrum of activity similar to that of other recent cephalosporins. In a clinical
trial, ceftobiprole was non-inferior to vancomycin for the treatment of MRSA-associated complicated
skin and skin structure infections (cSSSIs). Doripenem, a new carbapenem, has some activity against
MRSA, but otherwise has an anti-Gram-positive spectrum of activity similar to that of imipenem and an
anti-Gram-negative spectrum similar to that of meropenem. In a clinical trial, it was non-inferior to
meropenem for the treatment of complicated intra-abdominal infections. Iclaprim is a dihydrofolate
reductase inhibitor with greatly enhanced activity, as compared with trimethoprim, against a range of
Gram-positive and Gram-negative pathogens. The limited literature concerning this agent has
concentrated on its potential role in the treatment of infections with Gram-positive bacteria. A clinical
trial has demonstrated the non-inferiority of iclaprim, as compared with linezolid, in the treatment of
cSSSIs, including those associated with MRSA.
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INTRODUCTION
Antimicrobial resistance is an inevitable evolu-
tionary response to antimicrobial therapy. Signif-
icant penicillin resistance appeared in
Staphylococcus aureus within a year of the intro-
duction of penicillin, and multiple resistance
appeared in hospital strains a few years later [1].
Since the introduction of ﬂuoroquinolones into
clinical practice in the 1980s, resistance to these
compounds has become common in some bacte-
rial species, especially hospital strains of staphy-
lococci, Enterobacteriaceae and Pseudomonas
aeruginosa [2]. Glycopeptide resistance did not
emerge in enterococci until approximately
30 years after the discovery of vancomycin, but
this resistance was associated with increasing use
of vancomycin worldwide [3]. In contrast, occa-
sional strains that were resistant to linezolid
appeared during clinical trials even before the
drug was licensed for use [4].
In addition to selecting for resistance in tar-
geted species, antimicrobial therapy encourages
infections with inherently resistant opportunistic
pathogens in compromised patients. Thus, the
widespread use of sulphonamides and penicillins
that were effective against Gram-positive species
in the 1930s and 1940s was associated with an
increase in serious hospital infections due to
Gram-negative bacilli that were resistant to these
agents from the late 1940s onwards [5].
For some time, the pharmaceutical industry
kept pace with these changes by developing a
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stream of new agents that were active against
emerging resistant pathogens. However, impru-
dent antibiotic usage and poor infection control
measures have led to increasing resistance and
multiple resistance in many clinically impor-
tant bacteria. Prevalence varies with time and
place, but the rate of increase has accelerated over
the last 10–15 years, and most countries now have
signiﬁcant resistance problems. In 2004,Wenzel [6]
noted that in the USA, almost 50% of Streptococcus
pneumoniae isolates showed high or intermediate
levels of resistance to penicillin, 50% of hospital
isolates of S. aureus were methicillin-resistant,
30% of hospital-acquired enterococci were vanco-
mycin-resistant, and 20% and 15% of P. aeruginosa
isolates were quinolone- and imipenem-resistant,
respectively. Cephalosporin resistance, mediated
by the production of extended-spectrum b-lacta-
mases (ESBLs), is also common in Enterobacteria-
ceae and is increasing in community and hospital
isolates worldwide. Resistance rates among Gram-
positive and Gram-negative bacteria in intensive-
care units are particularly high, and reduce the
effectiveness of both older and newer antimicro-
bials [7,8]. Multiple drug resistance is compromis-
ing the treatment of serious bacterial infections,
and has led some clinicians to speculate that
we may be approaching the end of the ‘antibiotic
era’ [9–11].
The situation is aggravated by the apparent
lack of new antimicrobial agents on the horizon
[12]. In the 1930s and 1940s, four new classes
of antibiotics were approved (sulphonamides,
b-lactams, aminoglycosides, and chlorampheni-
col); in the 1950s and 1960s, six new classes were
licensed (tetracyclines, macrolides, glycopeptides,
rifamycins, quinolones, and trimethoprim); but
there were none licensed in the 30 years from the
1970s to the 1990s [6,13]. Since 2000, only three
antimicrobials of a new class, or subclass, have
been approved, two of them speciﬁcally for the
treatment of Gram-positive infections (the oxazo-
lidinone linezolid, and the cyclic lipopeptide
daptomycin), and one with more broad-spectrum
activity (the glycylcycline tigecycline) (Table 1)
[6,12,13].
Spellberg et al. found in 2004 that antibacterials
accounted for only six of 506 drugs under devel-
opment by the largest pharmaceutical and bio-
technology companies [14]. Barriers to the
development of novel antibacterial agents include
a lack of support for academic research, regula-
tory issues, and commercial risks that have
discouraged some pharmaceutical companies
from investing in this area [6,13–16].
Minimizing antibiotic resistance requires a
multidisciplinary response, including improve-
ments in prescribing practices, and in measures
for the prevention and control of hospital infec-
tions. New therapies, including new antimicrobial
agents with novel actions or newly discovered
targets, are also essential; however, the relatively
few new agents that have been introduced
recently have tended to target resistant Gram-
positive bacteria, with little signiﬁcant extension
of the antibacterial spectrum against resistant
Gram-negative bacteria [13].
Relatively few new antibacterial agents are
under development. This article will review three
investigational agents for which signiﬁcant data
are available to judge their safety and potential
effectiveness. They are ceftobiprole (a pyrrolidi-
none-3-ylidenemethyl cephem administered
intravenously as a prodrug), doripenem (a par-
enterally administered 1-b-methyl carbapenem),
and iclaprim (a diaminopyrimidine dihydrofolate
reductase (DHFR) inhibitor similar to trimetho-
prim, but with greater potency against speciﬁc
organisms). All of these compounds are currently
being evaluated in phase 3 studies. Their chem-
ical structures are shown in Fig. 1 [17–19].
CEFTOBIPROLE
Ceftobiprole medocaril (formerly known as
BAL5788) is the water-soluble prodrug of cefto-
biprole (a pyrrolidinone-3-ylidenemethyl cephem
Table 1. Spectra of antibiotics recently launched or antic-
ipatede
Gram-positive cocci Respiratory pathogens Broad spectrum
Quinupristin–dalfopristin
(not Enterococcus faecalis)
Telithromycinb Ertapenemd
Linezolid Peptide deformylase
inhibitors
Doripenemd
Daptomycin Moxiﬂoxacinc Tigecycline
Oritavancin Garenoxacinc Sitaﬂoxacin
Dalbavancin (not VanA
vancomycin-resistant
enterococci)
Gemiﬂoxacinc
Anti-MRSA cephalosporinsa
MRSA, methicillin-resistant Staphylococcus aureus.
aBroad-spectrum activity but targeting MRSA.
bWithdrawn from the market in 2006 for safety reasons.
cBroad-spectrum activity but targeting Streptococcus pneumoniae and no more
effective than ciproﬂoxacin against Gram-negative bacteria.
dNot active against strains resistant to existing carbapenems.
eAdapted from: Livermore [12].
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formerly known as BAL9141; see Fig. 1), which is
usually described as a novel broad-spectrum
cephalosporin [18]. It has in vitro activity against
methicillin-resistant S. aureus (MRSA), Enterococ-
cus faecalis and penicillin-resistant Streptococcus
pneumoniae, with MIC90 values (the minimal
concentrations that inhibit 90% of strains tested
in vitro) of 2–4 mg ⁄L [20], while retaining the anti-
Gram-negative activity of newer cephalosporins.
Schmitt-Hoffmann et al. reported that ceftobi-
prole has a predictable and stable pharmacoki-
netic proﬁle [18]. When it is given as ceftobiprole
medocaril to healthy male volunteer subjects over
8 days at doses of 500–750 mg once- to twice-
daily, serum concentrations are maintained above
the MICs for susceptible pathogens for prolonged
periods [18]. Ceftobiprole exhibits linear pharma-
cokinetics following multiple doses of 500–750 mg
twice-daily for 8 days, with an elimination half-
life of approximately 3 h and a steady-state
volume of distribution (Vss) of 16 ± 1.8 L, which
is approximately equal to the adult human extra-
cellular ﬂuid compartment [18]. Steady-state peak
plasma concentrations after 750 mg every 12 h for
8 days were 60.6 mg ⁄L [18]. Eliminated primarily
in urine (84%), ceftobiprole has a renal clearance
rate of 4.05 ± 0.47 L ⁄h, which corresponds to the
normal human glomerular ﬁltration rate. Ceftobi-
prole was safe and well tolerated in these subjects
[18].
Importantly, this pharmacokinetic study
showed that after multiple 750-mg infusions of
ceftobiprole medocaril, the mean concentrations
of ceftobiprole in plasma exceeded the MIC at
which 100% of MRSA isolates are inhibited
(4 mg ⁄L) for approximately 7–9 h (58–75% of a
12-h dosing interval) [18]. In view of its potency
against MRSA, ceftobiprole may represent an
advance in b-lactam therapy for these organisms,
while retaining the anti-Gram-negative activity of
third- or fourth-generation cephalosporins.
In vitro activity
For comparative purposes, Jones et al. proposed
tentative conservative breakpoints for ceftobipro-
le (based on values for cefepime, cefotaxime, and
ceftriaxone) of £4 mg ⁄L for enterococci, Entero-
bacteriaceae, non-enteric Gram-negative bacilli and
staphylococci, £2 mg ⁄L for Haemophilus spp., and
£1 mg ⁄L for streptococci [20]. On this basis,
ceftobiprole has potent bactericidal activity
against MRSA [20,21], E. faecalis (but not
Enterococcus faecium) [20], and penicillin-resistant
Streptococcus pneumoniae [20]. It has anti-Gram-
negative activity comparable to that of an
extended-spectrum cephalosporin [20]. It has some
activity against Gram-negative non-fermenters,
e.g. P. aeruginosa and Acinetobacter baumannii [22],
but it is not effective against ESBL-producing
Fig. 1. Chemical structures of:
ceftobiprole medocaril (formerly
BAL5788; water-soluble prodrug
for parenteral administration) and
its microbiologically active com-
pound, ceftobiprole (formerly
BAL9141); doripenem (formerly
S-4661), meropenem and imipenem;
iclaprim (formerly AR-100); and
trimethoprim. aAdapted from: Sch-
mitt-Hoffmann et al. [18]. bAdapted
from: Jones et al. [17]. cAdapted
from: Merrem IV Prescribing Infor-
mation. dAdapted from: Primaxin IV
Prescribing Information. eAdapted
from: Schneider et al. [19].
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Enterobacteriaceae [20]. Comparative in vitro activ-
ities of ceftobiprole and selected comparison
drugs are summarized in Table 2 [20–22].
The in vitro study by Jones et al. [20] compared
the activity of ceftobiprole with those of 12 other
antibiotics against 2263 clinical isolates (including
1097 Gram-positive isolates). This study found
ceftobiprole to have good activity against 96
oxacillin-resistant S. aureus isolates and 90 oxacil-
lin-resistant coagulase-negative staphylococci,
with MIC90 values of 2 mg ⁄L for both. The
ceftobiprole MIC90 values for Streptococcus
pneumoniae were £0.015, 0.12 and 0.25 mg ⁄L for
261 penicillin-sensitive, 145 penicillin-intermedi-
ate and 114 penicillin-resistant isolates, respec-
tively. The MIC90 for 62 E. faecalis isolates was
4 mg ⁄L, but it was >32 mg ⁄L for 52 E. faecium
isolates.
Bogdanovich et al. [21] tested 152 S. aureus
isolates, including ﬁve vancomycin-intermediate
and two vancomycin-resistant strains, and found
MIC90 values for ceftobiprole of 0.5 mg ⁄L for
methicillin-susceptible strains and 2 mg ⁄L for
methicillin-resistant strains. For 151 coagulase-
negative staphylococci (including four vancomy-
cin-intermediate strains), MIC90 values were 1
and 2 mg ⁄L for methicillin-susceptible and meth-
icillin-resistant isolates, respectively. Ceftobiprole
was bactericidal at a concentration of 2 mg ⁄L
against 11 of 12 staphylococcal strains, which
included the vancomycin-resistant and vancomy-
cin-intermediate coagulase-negative S. aureus
strains.
In the study by Jones et al. [20], ceftobiprole
was more effective than ceftriaxone against most
species of non-ESBL-producing Enterobacteriaceae
[20]. Neither ceftobiprole nor any of the other
advanced-generation cephalosporins were effec-
tive against ESBL-producing Klebsiella pneumoniae
or Escherichia coli (MIC90 values ‡16 mg ⁄L; see
Table 2) [20]. Ceftobiprole had activity compara-
ble to that of ceftriaxone against Gram-negative
respiratory pathogens such as Haemophilus inﬂu-
enzae (MIC90 values of 0.06–0.5 mg ⁄L, as com-
pared with 0.03 mg ⁄L for ceftriaxone) and
Moraxella catarrhalis (MIC90 of 0.5 mg ⁄L for both
ceftobiprole and ceftriaxone) [20].
Ceftobiprole has activity against some Gram-
negative non-fermenters, but species and strains
within species vary in their susceptibility [22].
Jones et al. found that 16 of 23 (69.6%) P. aerugin-
osa isolates and ten of 22 (45.5%) Acinetobacter
spp. isolates were susceptible [20]. Zbinden et al.
noted MIC90 values of 32 mg ⁄L for P. aeruginosa,
16 mg ⁄L for A. baumanii, <0.06 mg ⁄L for Acinet-
obacter lwofﬁ, and >64 mg ⁄L for Stenotrophomonas
maltophilia [22].
Ceftobiprole has variable activity against anaer-
obic bacteria in vitro. Wootton et al. [23] con-
ducted a study comparing the activity of
ceftobiprole with that of ten other antimicrobials
against various clinically signiﬁcant anaerobes. It
had poor activity against Bacteroides spp.; the
ceftobiprole MIC50 (the concentration that inhibits
50% of strains) for a variety of other Gram-
positive and Gram-negative anaerobes was
£1 mg ⁄L, but the MIC90 values ranged between
8 and >128 mg ⁄L.
Clinical studies
At present, there are limited clinical data available
concerning the efﬁcacy of ceftobiprole. Ceftobi-
prole is currently in phase 3 trials for complicated
skin and skin structure infections (cSSSIs) associ-
ated with MRSA, and for MRSA-related nosoco-
mial and community-acquired pneumonias.
Two phase 3 cSSSI studies of ceftobiprole were
completed in late 2006, and are referred to as the
STudy of Resistant Staphyloccocus aureus in Skin
and Skin structure infections (STRAUSS) trials.
The ﬁrst phase 3 cSSSI study of ceftobiprole
(STRAUSS I) was a multicentre, randomized,
double-blind study in which 784 patients with
MRSA-related cSSSIs were randomly assigned to
receive ceftobiprole 500 mg, or vancomycin 1 g,
every 12 h [24].
The study design of the STRAUSS I trial is
shown in Fig. 2, and the distribution of pathogens
according to genera and species is illustrated
in Fig. 3. As reported by Noel et al. [24], 226
microbiologically evaluable patients who received
ceftobiprole had a cure rate of 94.2%, as com-
pared with 93.5% of 217 microbiologically evalu-
able patients who received vancomycin (no
signiﬁcant difference, demonstrating non-inferi-
ority; see Fig. 2). Ceftobiprole was well tolerated,
and was as effective and as safe as vancomycin in
this study.
The majority of pathogens in this trial were
Gram-positive bacteria (isolated, after culture,
from 585 of 642 patients); of these, most were
S. aureus, with the remainder comprising coagu-
lase-negative staphylococci, streptococci, and
22 Clinical Microbiology and Infection, Volume 14, Supplement 6, December 2008
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other species. There were 57 patients with Gram-
negative isolates, mostly Enterobacteriaceae, with
the remainder comprising similar numbers of
Pseudomonas and Acinetobacter spp.; see Fig. 3
(Amsler et al., 46th Interscience Conference
on Antimicrobial Agents and Chemotherapy,
2006).
Because limited clinical data are available, the
efﬁcacy of ceftobiprole against infections caused
by Gram-negative pathogens, and its role in
treating anaerobic infections, remain to be
demonstrated [23].
DORIPENEM
Doripenem (formerly S-4661) is a parenterally
administered 1-b-methyl carbapenem that is sta-
ble in the presence of human renal dehydropep-
tidases [25] as well as ESBLs [26], with
pharmacokinetic and pharmacodynamic proper-
ties similar to those of meropenem [25]. Doripe-
nem displays low protein binding (9%) and has a
short elimination half-life (1 h), with elimination
being primarily through renal mechanisms
(approximately 75% of the parent drug is
Fig. 2. Study design of STudy of
Resistant Staphyloccocus aureus in
Skin and Skin structure infections
(STRAUSS) I trial (ceftobiprole
phase 3 registration study). cSSSI,
complicated skin and skin structure
infection. Adapted from: Noel et al.
[24].
Gram-negative
pathogens
(n = 57)
Gram-positive
pathogens
(n = 585)
Staphylococcus
aureus
Other
Streptococcus spp.
Coagulase-negative
staphylococci
Enterobacteriacea
Other
All pathogens
(n = 642)
Pseudomonas spp.
Acinetobacter spp.
Gram-negative
Gram-positive
n = 585
n = 57
Fig. 3. Results of STudy of Resis-
tant Staphyloccocus aureus in Skin
and Skin structure infections
(STRAUSS) I trial (ceftobiprole
phase 3 registration study), showing
the distribution of pathogens over-
all, and according to genera and
species. Adapted from: Amsler et al.,
46th Interscience Conference on
Antimicrobial Agents and Chemo-
therapy, 2006.
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excreted unchanged) [27]. The pharmacokinetic
proﬁle of doripenem after a single 500-mg intra-
venous dose is characterized by a Cmax of
20 mg ⁄L, an AUC of 44 mg h ⁄L, and a Vss of
13–21 L. Like other carbapenems, doripenem is
not stable in the presence of the L1 enzyme found
in Stenotrophomonas maltophilia [28].
The chemical structures of doripenem [17],
meropenem (Merrem IV Prescribing Information)
and imipenem (Primaxin IM Prescribing Infor-
mation) are shown in Fig. 1.
In vitro activity
Fritsche et al. [28] evaluated the in vitro activity of
doripenem against 16 008 clinical bacterial iso-
lates collected in an international surveillance
project during 2003. Doripenem had an anti-
Gram-positive spectrum of activity similar to that
of imipenem [28], and an anti-Gram-negative
spectrum similar to that of meropenem [28]. As
compared with earlier carbapenems, doripenem
is more active against oxacillin-susceptible S. aur-
eus and coagulase-negative staphylococci (2705
and 297 isolates, respectively; MIC90 of
0.06 mg ⁄L), but has similar activity against Strep-
tococcus pneumoniae and E. faecalis [28]. Doripe-
nem was four-fold to 32-fold more active than
imipenem against Enterobacteriaceae, which is sim-
ilar to the activity of meropenem [28]. This study
did not test doripenem against MRSA. Table 3
summarizes the in vitro susceptibility results of
doripenem from this study [28].
Jones et al. evaluated the activity of doripenem
against a challenging collection of 394 clinical
isolates with deﬁned resistance phenotypes and
genotypes [17]. This collection included 16 strains
of methicillin-resistant (oxacillin-resistant) S. aur-
eus, for which doripenem demonstrated an MIC
range of 0.25–32 mg ⁄L (MIC90 of 16 mg ⁄L) [17].
Two studies by the same group [26] showed
that doripenem is stable in the presence of ESBLs.
It had MIC90 values between 0.03 and 0.016 mg ⁄L
when tested against ESBL-producing Escherichia
coli [17,26], values that were lower than those for
ertapenem [17,26], imipenem, and meropenem
[17]. This superiority to other carbapenems was
also shown for ESBL-producing K. pneumoniae, for
which doripenem had an MIC90 of 0.06 mg ⁄L, as
compared with 0.12 mg ⁄L for meropenem and
0.25 mg ⁄L for ertapenem and imipenem.
Fritsche et al. also found doripenem to be more
active against P. aeruginosa and Acinetobacter spp.
than meropenem and ceftazidime [28]. Doripe-
nem seems to be more active against clinical
strains of P. aeruginosa isolated in North America
than against those from Europe and Latin Amer-
ica. Table 4 shows the cumulative percentages of
P. aeruginosa isolates from different geographical
regions that were susceptible to each concentra-
tion of doripenem as compared with meropenem
and imipenem [28].
These ﬁndings conﬁrm the activity of doripe-
nem against a broad variety of clinical isolates
worldwide. Like other carbapenems, doripenem
may therefore be useful for the treatment of
Table 3. In vitro activities of doripenem (formerly S-4661) against various classes of organismsa
MIC90 (mg ⁄L) for Gram-positive cocci
Organism Doripenem Imipenem Meropenem Ceftriaxone Levoﬂoxacin
OSSA (n = 2705) 0.06 £0.5 0.12 4 0.5
OSCoNS (n = 297) 0.06 £0.5 0.12 4 2
Enterococcus faecalis (n = 1206) and
other non-faecium species (n = 70)
8 4 16 >32 >4
Streptococcus pneumoniae (n = 885) 0.5 £0.5 0.5 1 2
MIC90 (mg ⁄L) for wild-type Enterobacteriaceae
Doripenem Imipenem Meropenem Ceftriaxone Levoﬂoxacin
Escherichia coli (n = 3023) 0.03 £0.5 0.03 >32 >4
Klebsiella spp. (n = 1107) 0.06 £0.5 0.03 32 2
Enterobacter spp. (n = 601) 0.12 1 0.12 >32 >4
MIC90 (mg ⁄L) for Gram-negative non-fermenters
Doripenem Imipenem Meropenem Ceftazidime Levoﬂoxacin
Pseudomonas aeruginosa (n = 829) 8 >8 16 >16 >4
Acinetobacter spp. (n = 155) 4 2 8 >16 >4
Burkholderia cepacia (n = 20) 8 8 4 4 4
Stenotrophomonas maltophilia (n = 80) >16 >8 >16 >16 4
OSSA, oxacillin-sensitive Staphylococcus aureus; OSCoNS, oxacillin-sensitive coagulase-negative Staphylococcus.
aAdapted from: Fritsche et al. [28].
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infections caused by pathogens resistant to other
classes of drugs [17].
Clinical studies
Malafaia et al. (46th Interscience Conference on
Antimicrobial Agents and Chemotherapy, 2006,
Presentation No. L-1564b) reported a clinical trial
comparing doripenem with meropenem for the
treatment of complicated intra-abdominal infec-
tions. Doripenem was generally well tolerated
and was non-inferior to meropenem in this
phase 3 study. The study design is shown in
Fig. 4. It was a randomized, double-blind, double-
dummy, multicentre study comparing intrave-
nous doripenem (500 mg every 8 h; 242 patients)
with intravenous meropenem (1 g every 8 h; 233
patients), with an intravenous-to-oral switch to
amoxycillin–clavulanate after ‡9 doses of either
carbapenem. The primary endpoint was clinical
response (cure or failure) at the test-of-cure visit
21–60 days post-therapy. In microbiologically
evaluable patients, the cure rate was 83.3% with
doripenem and 83.0% with meropenem (not
signiﬁcantly different), thus demonstrating the
non-inferior efﬁcacy of doripenem as compared
with meropenem (see Fig. 4).
ICLAPRIM
Iclaprim, formerly AR-100, is a compound syn-
thesized by rational design, based on the structure
of the widely used DHFR inhibitor trimethoprim.
These agents inhibit bacterial DHFR, an enzyme
that is necessary for folate synthesis and DNA
replication. Iclaprim selectively inhibits bacterial
DHFR at submicromolar concentrations, but
Table 4. Pseudomonas aeruginosa isolates from different
regions that were susceptible to doripenem and other
carbapenemsa
Region (no.
of isolates)
Carbapenem
tested
Cumulative percentages of susceptible
isolates at each concentration (mg ⁄L)
0.05 1 2 4 8 16
North America (226)
Doripenem 69 87 92 96 98 100
Meropenem 66 84 90 93 96 100
Imipenem 15 69 89 91 94 100
Europe (450)
Doripenem 53 73 79 86 92 100
Meropenem 54 68 75 83 88 100
Imipenem 11 59 74 80 85 100
Latin America (153)
Doripenem 44 59 65 76 90 100
Meropenem 42 56 63 71 79 100
Imipenem 11 51 65 67 79 100
aAdapted from: Fritsche et al. [28].
Fig. 4. Study design of doripenem
phase 3 registration study. IV, intra-
venous; PO, oral. Adapted from:
Malafaia et al., 46th Interscience
Conference on Antimicrobial Agents
and Chemotherapy, 2006, Presenta-
tion No. L-1564b.
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causes little or no inhibition of the human iso-
zyme at concentrations more than ﬁve orders of
magnitude higher [19].
The pharmacokinetics of intravenous iclaprim
after single doses (0.4 or 0.8 mg ⁄kg infused over
30 min) and multiple doses (60 and 120 mg ⁄day
infused over 20 min twice-daily for 10 days) were
investigated in healthy volunteers [29]. The elim-
ination half-life was dose-independent, and ran-
ged from 2.3 to 3.6 h. Both Cmax and AUC values
increased proportionally to dose. Total plasma
clearance ranged from approximately 7.8 to
9.2 mL ⁄min ⁄kg. Iclaprim had good tissue distri-
bution, based on a mean Vss of 1300–1680 mL ⁄ kg
from these studies.
Pharmacokinetic parameters remained unchan-
ged after multiple dosing, with little drug
accumulation. Preliminary data also demonstrated
that iclaprim has moderate oral bioavailability
(40%), which may permit intravenous-to-
oral switch therapy in the treatment of some
infections.
Although it is similar to trimethoprim in
structure (Fig. 1), iclaprim shows markedly more
potent in vitro activity against both Gram-nega-
tive and Gram-positive pathogens, particularly
staphylococci [19]. It is active against S. aureus
isolates that are resistant to methicillin–oxacillin.
It is also noteworthy that iclaprim was rapidly
bactericidal against Gram-positive pathogens (e.g.
S. aureus, penicillin-sensitive and penicillin-resis-
tant streptococci, and vancomycin-sensitive and
vancomycin-resistant E. faecalis) at concentrations
near MIC values [29]. It has been suggested that
the activity of iclaprim against trimethoprim-
resistant bacteria is due to its enhanced afﬁnity
for bacterial DHFR. Thus, iclaprim is potentially
useful for the treatment of nosocomial infections
caused by both Gram-positive and Gram-nega-
tive, multiresistant bacteria.
In vitro activity
Table 5 summarizes the in vitro activity of icla-
prim [19]. The MIC90 values show that iclaprim is
generally more potent than trimethoprim, vanco-
mycin, linezolid and erythromycin against sus-
ceptible Gram-positive and Gram-negative
species. Iclaprim has lower MIC90 values for the
key Gram-positive pathogens, e.g. MRSA, Strep-
tococcus pyogenes and enterococci, than trimetho-
prim, vancomycin, and linezolid. However, it has
slightly higher MIC90 values for penicillin-resis-
tant Streptococcus pneumoniae than vancomycin
and linezolid [19].
Iclaprim also has potent activity against the
Gram-negative respiratory pathogens H. inﬂuen-
zae, M. catarrhalis and Chlamydia pneumoniae
[19,30]. It is more active than levoﬂoxacin against
Chlamydia trachomatis, but slightly less active than
azithromycin [30]. Table 6 shows the in vitro
activity of iclaprim against ten isolates of C. tra-
chomatis and ten isolates of C. pneumoniae [30].
Clinical studies
As with the other two agents discussed here, there
are limited clinical trial data available for icla-
Table 5. Comparative antibacterial
activities of iclaprim and other anti-
biotics against Gram-positive and
Gram-negative bacteriaa
Organism
MIC90 (mg ⁄L)
Iclaprim Trimethoprim Vancomycin Linezolid Erythromycin
Staphylococcus aureus (MSSA) 0.06 16 1 8 1
S. aureus (MRSA) 0.06 8 1 8 16
Streptococcus pyogenes 0.03 64 1 2 32
Streptococcus agalactiae 0.5 128 0.5 2 8
Streptococcus pneumoniae (PEN-R) 4 >128 1 2 32
Enterococcus spp. 0.12 8 2 4 32
Haemophilus inﬂuenzae 0.5 1 128 64 8
Moraxella catarrhalis 4 128 64 8 0.25
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; PEN-R, penicillin resistance.
aAdapted from: Schneider et al. [19].
Table 6. In vitro activity of iclaprim against ten isolates of
Chlamydia trachomatis and ten isolates of Chlamydia pneu-
moniaea[30]
Antibiotic Organism
MIC (mg ⁄L) MBC (mg ⁄L)
Range 50% 90% Range 90%
Iclaprim C. trachomatis 0.5 0.5 0.5 0.5 0.5
C. pneumoniae 0.5 0.5 0.5 0.5 0.5
Levoﬂoxacin C. trachomatis 0.5–1 0.5 1 0.5 1
C. pneumoniae 0.5–1 0.5 0.5 0.5–1 0.5
Azithromycin C. trachomatis 0.062–0.125 0.062 0.125 0.062–0.125 0.125
C. pneumoniae 0.062–0.125 0.062 0.125 0.062–0.125 0.125
MBC, minimum bactericidal concentration.
aAdapted from: Kohlhoff et al. [30].
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prim. It is currently in phase 3 evaluation for
cSSSIs.
The ASSIST I study is a phase 3 evaluation
whose design is shown in Fig. 5. This clinical trial
demonstrated the non-inferiority of iclaprim, as
compared with linezolid, in both efﬁcacy and
safety in treating adult patients with cSSSIs,
including those associated with MRSA. S. aureus
was the most common baseline pathogen in this
trial, with approximately 70% of isolates, and up
to 25% of these were MRSA. The cure rate in the
microbiologically evaluable population at the test-
of-cure visit was 94.7% for iclaprim, as compared
with 98.8% for linezolid (not signiﬁcantly differ-
ent), thus demonstrating non-inferiority. Patients
who received iclaprim experienced fewer adverse
events than those who received linezolid (18.1%
vs. 25.1%).
In summary, iclaprim is a novel DHFR inhib-
itor that is effective against mainly multiresistant
Gram-positive organisms, including MRSA. It has
some anti-Gram-negative activity, and also has a
potential role in the treatment of respiratory
infections caused by C. pneumoniae and genital
infections caused by C. trachomatis.
CONCLUSIONS
This article has reviewed the available data on
three new antibacterials of different classes that
are currently in development. The cephalosporin
ceftobiprole has welcome activity against MRSA
but no additional activity against Gram-negative
species, as compared with available cephalospo-
rins. It was non-inferior to vancomycin in the
treatment of cSSSIs associated with MRSA. Do-
ripenem, the newest agent of the carbapenem
class, has a spectrum similar to that of other
carbapenems and some activity against MRSA. It
was non-inferior to meropenem in the treatment
of complicated intra-abdominal infections. The
DHFR inhibitor iclaprim offers greatly enhanced
activity against a range of pathogens, as com-
pared with trimethoprim, and is very active
against some Chlamydia species. It is more active
than trimethoprim, vancomycin and linezolid
against key Gram-positive pathogens, and the
limited literature concerning this agent has con-
centrated on its potential role in the treatment of
infections with these organisms. It was non-
inferior to linezolid in the treatment of cSSSIs,
Fig. 5. Study design of ASSIST I
trial (iclaprim phase 3 registration
study). cSSSI, complicated skin and
skin structure infection; MRSA,
methicillin-resistant Staphylococcus
aureus; IV, intravenous; ITT, inten-
tion-to-treat. Adapted from: Arpida
press release (http://www.arpida.
ch/users/1/content/assist-1_results_
en.pdf?way2go=379f5f1fe9512a9ea14
a3cf340abb953) (accessed 23 April
2008).
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including those caused by MRSA. An assessment
of the potential clinical roles of these three
interesting agents must await the results of
further clinical trials.
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